These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38704502)

  • 1. Residual Axillary Metastases in Node-Positive Breast Cancer Patients After Neoadjuvant Treatment: A Register-Based Study.
    Munck F; Jensen MB; Vejborg I; Gerlach MK; Maraldo MV; Kroman NT; Tvedskov THF
    Ann Surg Oncol; 2024 Aug; 31(8):5157-5167. PubMed ID: 38704502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted axillary dissection reduces residual nodal disease in clinically node- positive breast cancer after neoadjuvant chemotherapy.
    Cabıoğlu N; Karanlık H; Yılmaz R; Emiroğlu S; Tükenmez M; Bademler S; Şimşek DH; Kantarcı TR; Yirgin İK; Bayram A; Dursun M
    World J Surg Oncol; 2024 Jul; 22(1):178. PubMed ID: 38971793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a predictive score of axillary lymph node dissection based on targeted axillary dissection in patients with breast cancer diagnosis, affected lymph nodes, and neoadjuvant treatment.
    Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
    Surg Oncol; 2021 Sep; 38():101629. PubMed ID: 34171793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility and validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Definitive results.
    Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
    Surg Oncol; 2021 Sep; 38():101636. PubMed ID: 34303211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer.
    Kuemmel S; Heil J; Bruzas S; Breit E; Schindowski D; Harrach H; Chiari O; Hellerhoff K; Bensmann E; Hanf V; Graßhoff ST; Deuschle P; Belke K; Polata S; Paepke S; Warm M; Meiler J; Schindlbeck C; Ruhwedel W; Beckmann U; Groh U; Dall P; Blohmer JU; Traut A; Reinisch M
    JAMA Surg; 2023 Aug; 158(8):807-815. PubMed ID: 37285140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncologic Outcomes for Different Axillary Staging Techniques in Patients with Nodal-Positive Breast Cancer Undergoing Neoadjuvant Systematic Treatment: A Cancer Registry Study.
    Pfob A; Kokh DB; Surovtsova I; Riedel F; Morakis P; Heil J
    Ann Surg Oncol; 2024 Jul; 31(7):4381-4392. PubMed ID: 38710911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of traditional targeted axillary dissection eligibility criteria for node-positive breast cancer after neoadjuvant chemotherapy in a prospective multicenter registry.
    Loveland-Jones C; Gaughan J; Caudle A; Murphy B; Samiian L; Byrum S; Brill K; Germaine P; Zhang X; Yoon-Flannery K; Carter T; Lopez A; Gruner R; Fantazzio M; Kuerer H
    Eur J Surg Oncol; 2024 Apr; 50(4):108245. PubMed ID: 38484493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy.
    Montagna G; Mrdutt MM; Sun SX; Hlavin C; Diego EJ; Wong SM; Barrio AV; van den Bruele AB; Cabioglu N; Sevilimedu V; Rosenberger LH; Hwang ES; Ingham A; Papassotiropoulos B; Nguyen-Sträuli BD; Kurzeder C; Aybar DD; Vorburger D; Matlac DM; Ostapenko E; Riedel F; Fitzal F; Meani F; Fick F; Sagasser J; Heil J; Karanlik H; Dedes KJ; Romics L; Banys-Paluchowski M; Muslumanoglu M; Perez MDRC; Díaz MC; Heidinger M; Fehr MK; Reinisch M; Tukenmez M; Maggi N; Rocco N; Ditsch N; Gentilini OD; Paulinelli RR; Zarhi SS; Kuemmel S; Bruzas S; di Lascio S; Parissenti TK; Hoskin TL; Güth U; Ovalle V; Tausch C; Kuerer HM; Caudle AS; Boileau JF; Boughey JC; Kühn T; Morrow M; Weber WP
    JAMA Oncol; 2024 Jun; 10(6):793-798. PubMed ID: 38662396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wire guided localisation for targeted axillary node dissection is accurate in axillary staging in node positive breast cancer following neoadjuvant chemotherapy.
    Balasubramanian R; Morgan C; Shaari E; Kovacs T; Pinder SE; Hamed H; Sever AR; Kothari A
    Eur J Surg Oncol; 2020 Jun; 46(6):1028-1033. PubMed ID: 31879050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of the Targeted Axillary Dissection Procedure in Clinically Node-Positive Breast Cancer: A Retrospective Analysis.
    Nijveldt JJ; Rajan KK; Boersma K; Noorda EM; van der Starre-Gaal J; Kate MV'V; Roeloffzen EMA; Vendel BN; Beek MA; Francken AB
    Ann Surg Oncol; 2024 Jul; 31(7):4477-4486. PubMed ID: 38523225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer.
    Kuerer HM; Newman LA; Buzdar AU; Hunt KK; Dhingra K; Buchholz TA; Binkley SM; Ames FC; Feig BW; Ross MI; Hortobagyi GN; Singletary SE
    Am J Surg; 1998 Dec; 176(6):502-9. PubMed ID: 9926779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Loss of Lymph Node Metastases After Neoadjuvant Chemotherapy in Patients With Cytology-proven Axillary Node-positive Primary Breast Cancer.
    Namura M; Tsunoda H; Kobayashi D; Enokido K; Yoshida A; Watanabe T; Suzuki K; Nakamura S; Yamauchi H; Hayashi N
    Clin Breast Cancer; 2019 Aug; 19(4):278-285. PubMed ID: 30975473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study.
    Wu SY; Li JW; Wang YJ; Jin KR; Yang BL; Li JJ; Yu XL; Mo M; Hu N; Shao ZM; Liu GY
    Int J Surg; 2023 Jul; 109(7):1863-1870. PubMed ID: 37132193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.
    Caudle AS; Yang WT; Krishnamurthy S; Mittendorf EA; Black DM; Gilcrease MZ; Bedrosian I; Hobbs BP; DeSnyder SM; Hwang RF; Adrada BE; Shaitelman SF; Chavez-MacGregor M; Smith BD; Candelaria RP; Babiera GV; Dogan BE; Santiago L; Hunt KK; Kuerer HM
    J Clin Oncol; 2016 Apr; 34(10):1072-8. PubMed ID: 26811528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SAVI SCOUT® localization of metastatic axillary lymph node prior to neoadjuvant chemotherapy for targeted axillary dissection: a pilot study.
    Baker JL; Haji F; Kusske AM; Fischer CP; Hoyt AC; Thompson CK; Lee MK; Attai D; DiNome ML
    Breast Cancer Res Treat; 2022 Jan; 191(1):107-114. PubMed ID: 34652548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrasound guided tattooing of axillary lymph nodes in breast cancer patients prior to neoadjuvant therapy, and identification of tattooed nodes at the time of surgery.
    Allweis TM; Menes T; Rotbart N; Rapson Y; Cernik H; Bokov I; Diment J; Magen A; Golan O; Levi-Bendet N; Givon Madhala O; Grubstein A
    Eur J Surg Oncol; 2020 Jun; 46(6):1041-1045. PubMed ID: 31801656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Axillary Dissection with
    Munck F; Andersen IS; Vejborg I; Gerlach MK; Lanng C; Kroman NT; Tvedskov THF
    Ann Surg Oncol; 2023 Jul; 30(7):4135-4142. PubMed ID: 37062781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraoperative Touch Imprint Cytology in Targeted Axillary Dissection After Neoadjuvant Chemotherapy for Breast Cancer Patients with Initial Axillary Metastasis.
    Wu S; Wang Y; Zhang N; Li J; Xu X; Shen J; Liu G
    Ann Surg Oncol; 2018 Oct; 25(11):3150-3157. PubMed ID: 30083833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axillary lymph node dissection in node-positive breast cancer: are ten nodes adequate and when is enough, enough?
    Rosenberger LH; Ren Y; Thomas SM; Greenup RA; Fayanju OM; Hwang ES; Plichta JK
    Breast Cancer Res Treat; 2020 Feb; 179(3):661-670. PubMed ID: 31741179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted axillary dissection after neoadjuvant chemotherapy for highly selective patients with initial cN1 breast cancer: A single-center prospective trial.
    Chen X; Lu Z; Wang C; Lyu M; Qiao J; Sun X; Li L; Zhang C; Liu Z
    Chin Med J (Engl); 2024 Jun; 137(12):1421-1430. PubMed ID: 38557731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.